// App-Quantinova.ai

e16020 : Efficacy and safety of camrelizumab combined with FLOT versus FLOT alone as neoadjuvant therapy in patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.

Researchers

Presenter

  • Ning Liu

Principal Investigators

  • Zimin Liu

  • Yanbing Zhou

  • Zhaojian Niu

  • Haitao Jiang

  • Yingqian Zhu

  • Huiyun Wang

  • Xiaoxiao Li

  • Shanai Song

  • Xiaodong Liu

  • Zequn Li

  • Shufen Zhao

Medical Centers

  • Oncology Department, the Affiliated Hospital of Qingdao University, Qingdao,...

  • Gastrointestinal Surgery,The Affiliated Hospital of Qingdao University, Qingdao, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastroesophageal junction (GEJ) adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Camrelizumab

  • Oxaliplatin

  • leucovorin

  • Docetaxel

  • Adrucil injection

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved